Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 121 institutions reported holding it in 13F filings for Q3 2026, worth $168.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $103.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +20 vs. previous quarter
- 121
- 13F valueReported value at the end of Q3 2026
- $168.2M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $30.9M
- +36.8% year over year
- Net income, FY2025
- -$74.3M
- No comparable prior period
- Free cash flow, FY2025
- -$86.1M
- No comparable prior period
- Revenue, Q3 FY2026
- $83.5M
- +924.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $74.3M (240.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.25M
- Shares sold short
- Change
- −203.2K
- −8.3% vs. previous
- Days to cover
- 3.90
- At average daily volume
Superinvestors holding FHTX, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding FHTX at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Foghorn Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2024 (view filing) | Sep 20-23 | 4 days | Costa CarlosChief People Officer | SSale | −36.6K | $10.04 | −$367.7K | −100.0%0 after | 2 lots10b5-1 |
| Sep 20, 2024 (view filing) | Sep 18 | 2 days | Costa CarlosChief People Officer | SSale | −11.6K | $10.05 | −$116.3K | −100.0%0 after | 10b5-1 |
| Sep 18, 2024 (view filing) | Sep 16-17 | 2 days | Costa CarlosChief People Officer | SSale | −10.7K | $10.04 | −$107.1K | −100.0%0 after | 2 lots10b5-1 |
| Sep 11, 2024 (view filing) | Sep 9 | 2 days | Bellon Steven F.Chief Scientific Officer | SSale | −20.0K | $9.50 | −$190.0K | −16.4%102.0K after | 10b5-1 |
| May 24, 2024 (view filing)5:05 PM ET | May 22 | 2 days | Afeyan Noubar and 3 others10% Owner | PPurchase | +3.63M | $5.51 | +$20.0M | –1.81M after | Derivative2 lots |
| Mar 12, 2024 (view filing) | Mar 11 | 1 day | Cavalie FannyChief Strategy/Bus Ops Officer | SSale | −11.0K | $6.56 | −$72.2K | −12.6%76.0K after | |
| Aug 18, 2023 (view filing) | Aug 16 | 2 days | Agresta SamuelChief Medical Officer | SSale | −311.3K | $8.25 | −$2.57M | −100.0%0 after |
Top 10 13F holders, Q3 2026
See all 121 holdersThe largest institutional positions in Foghorn Therapeutics Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 12,674,120 | $45.2M | 2.31% | 00.0% | Unchanged |
| BVF Inc | 5,842,000 | $20.9M | 0.69% | 00.0% | Unchanged |
| FMR LLC | 5,546,349 | $19.8M | 0.00% | −159,609−2.8% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 4,394,367 | $15.7M | 0.24% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,065,236 | $10.9M | 0.00% | +438,404+16.7% | Added |
| Raymond James Financial Inc | 2,479,621 | $8.85M | 0.00% | −10,357−0.4% | Reduced |
| Vanguard Capital Management LLC | 1,586,219 | $5.66M | 0.00% | +91,608+6.1% | Added |
| Euclidean Capital LLC | 1,573,761 | $5.62M | 1.74% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 861,655 | $3.08M | 0.00% | −49,211−5.4% | Reduced |
| Siren, L.L.C. | 720,720 | $2.57M | 0.06% | 00.0% | Unchanged |
Holders of 5% or more of FHTX
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Foghorn Therapeutics Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Flagship Ventures Fund V, L.P. | 13D/A | 27.20%20.8M shares | – | May 24, 20242 filings | Jan 13, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 14.30%8.51M shares | +4.31 ppfrom 9.99% | May 30, 20243 filings | Oct 5, 2026 | SEC |
| FMR LLC | 13G/A | 11.60%6.79M shares | +1.40 ppfrom 10.20% | Feb 8, 20217 filings | May 6, 2026 | SEC |
| Flynn James E | 13G/A | 8.64%5.14M shares | – | Sep 20, 20242 filings | May 14, 2026 | SEC |